Literature DB >> 7480538

Contrasting effects on methamphetamine sensitization of ceruletide, a cholecystokinin-like decapeptide, and haloperidol.

H Kuribara1.   

Abstract

Ceruletide, a cholecystokinin-like decapeptide, and haloperidol show neuroleptic actions through inhibition of dopamine release and blockade of dopamine receptors, respectively. In this study, the effects of both drugs on methamphetamine sensitization were assessed by means of ambulation in mice. The enhancement in ambulation increase caused by five repeated administrations of methamphetamine (2 mg/kg, SC) at 3- to 4-day intervals was dose-dependently reduced when it was administered simultaneously with ceruletide (0.01-0.1 mg/kg, SC) or haloperidol (0.03-0.3 mg/kg, SC). However, only haloperidol could inhibit the induction of methamphetamine sensitization as assessed by challenge with methamphetamine alone. Post-treatment with ceruletide (0.03 mg/kg) 3 h after each methamphetamine accelerated, whereas such post-treatment with ceruletide (0.1 mg/kg) or haloperidol (0.03-0.3 mg/kg) delayed, the induction of methamphetamine sensitization. On the other hand, mice given five pretreatments with ceruletide (0.01-0.1 mg/kg) or haloperidol (0.03-0.3 mg/kg) at 3- to 4-day intervals did not exhibit any significant change in the sensitivity to methamphetamine. The present results suggest that, in contrast to the dose-dependent inhibition of methamphetamine sensitization in the simultaneous administration and post-treatment schedules, although both drugs can antagonize the acute stimulant effect of methamphetamine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7480538     DOI: 10.1007/bf02246147

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Effects of ceruletide, administered singly and in combination with central-acting drugs, on discrete shuttle avoidance response in mice.

Authors:  H Kuribara; T Asami; I Ida; S Tadokoro
Journal:  Jpn J Pharmacol       Date:  1990-11

2.  Effects of YM-09151-2, a potent and selective dopamine D2 antagonist, on the ambulation-increasing effect of methamphetamine in mice.

Authors:  H Kuribara; S Tadokoro
Journal:  Jpn J Pharmacol       Date:  1990-03

Review 3.  [Modification of the behavioral effects of drugs after repeated administration--special reference to the reverse tolerance of amphetamines].

Authors:  S Tadokoro; H Kuribara
Journal:  Nihon Yakurigaku Zasshi       Date:  1990-05

4.  Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy.

Authors:  D S Segal; A J Mandell
Journal:  Pharmacol Biochem Behav       Date:  1974 Mar-Apr       Impact factor: 3.533

5.  Acute versus chronic effects of psychotropic drugs: adaptative responses in brain amine systems and their clinical implications. Evidence for multiphasic presynaptic adaptation: studies with cocaine and lithium [proceedings].

Authors:  A J Mandell; S Knapp
Journal:  Psychopharmacol Bull       Date:  1977-01

6.  Differential cataleptogenic and antistereotypic effects of caerulein and haloperidol.

Authors:  G Zetler
Journal:  Neuropharmacology       Date:  1981-07       Impact factor: 5.250

7.  Isolation and structure of caerulein, an active decapeptide from the skin of Hyla caerulea.

Authors:  A Anastasi; V Erspamer; R Endean
Journal:  Experientia       Date:  1967-09-15

8.  Localized intracaudate dopamine D2 receptor activation during the post-training period improves memory for visual or olfactory conditioned emotional responses in rats.

Authors:  N M White; M Viaud
Journal:  Behav Neural Biol       Date:  1991-05

Review 9.  Minireview. The ascent of cholecystokinin (CCK) - from gut to brain.

Authors:  J E Morley
Journal:  Life Sci       Date:  1982-02-07       Impact factor: 5.037

10.  Can posttreatment with the selective dopamine D2 antagonist, YM-09151-2, inhibit induction of methamphetamine sensitization? Evaluation by ambulatory activity in mice.

Authors:  H Kuribara
Journal:  Pharmacol Biochem Behav       Date:  1994-10       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.